These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 32105362)

  • 1. Kinetics of pH-dependent interactions between PD-1 and PD-L1 immune checkpoint proteins from molecular dynamics.
    Klyukin K; Alexandrov V
    Proteins; 2020 Sep; 88(9):1162-1168. PubMed ID: 32105362
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Investigation of protein-protein interactions and hot spot region between PD-1 and PD-L1 by fragment molecular orbital method.
    Lim H; Chun J; Jin X; Kim J; Yoon J; No KT
    Sci Rep; 2019 Nov; 9(1):16727. PubMed ID: 31723178
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular dynamics simulations elucidate conformational selection and induced fit mechanisms in the binding of PD-1 and PD-L1.
    Liu W; Huang B; Kuang Y; Liu G
    Mol Biosyst; 2017 May; 13(5):892-900. PubMed ID: 28327740
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular dynamics of the immune checkpoint programmed cell death protein I, PD-1: conformational changes of the BC-loop upon binding of the ligand PD-L1 and the monoclonal antibody nivolumab.
    Roither B; Oostenbrink C; Schreiner W
    BMC Bioinformatics; 2020 Dec; 21(Suppl 17):557. PubMed ID: 33308148
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structural Biology of the Immune Checkpoint Receptor PD-1 and Its Ligands PD-L1/PD-L2.
    Zak KM; Grudnik P; Magiera K; Dömling A; Dubin G; Holak TA
    Structure; 2017 Aug; 25(8):1163-1174. PubMed ID: 28768162
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structure-based derivation and intramolecular cyclization of peptide inhibitors from PD-1/PD-L1 complex interface as immune checkpoint blockade for breast cancer immunotherapy.
    Zhou K; Lu J; Yin X; Xu H; Li L; Ma B
    Biophys Chem; 2019 Oct; 253():106213. PubMed ID: 31276987
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular Modeling Studies on the Binding Mode of the PD-1/PD-L1 Complex Inhibitors.
    Almahmoud S; Zhong HA
    Int J Mol Sci; 2019 Sep; 20(18):. PubMed ID: 31546905
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structure of the Complex of Human Programmed Death 1, PD-1, and Its Ligand PD-L1.
    Zak KM; Kitel R; Przetocka S; Golik P; Guzik K; Musielak B; Dömling A; Dubin G; Holak TA
    Structure; 2015 Dec; 23(12):2341-2348. PubMed ID: 26602187
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structure and Dynamics of PD-L1 and an Ultra-High-Affinity PD-1 Receptor Mutant.
    Pascolutti R; Sun X; Kao J; Maute RL; Ring AM; Bowman GR; Kruse AC
    Structure; 2016 Oct; 24(10):1719-1728. PubMed ID: 27618663
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structural Insights of PD-1/PD-L1 Axis: An
    Rohit S; Patel M; Jagtap Y; Shah U; Patel A; Patel S; Solanki N
    Curr Protein Pept Sci; 2024; 25(8):638-650. PubMed ID: 38706351
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Blockade of the checkpoint PD-1 by its ligand PD-L1 and the immuno-oncological drugs pembrolizumab and nivolumab.
    Tavares ABMLA; Lima Neto JX; Fulco UL; Albuquerque EL
    Phys Chem Chem Phys; 2021 Sep; 23(37):21207-21217. PubMed ID: 34533552
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A high-affinity human PD-1/PD-L2 complex informs avenues for small-molecule immune checkpoint drug discovery.
    Tang S; Kim PS
    Proc Natl Acad Sci U S A; 2019 Dec; 116(49):24500-24506. PubMed ID: 31727844
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Understanding the structural and energetic basis of PD-1 and monoclonal antibodies bound to PD-L1: A molecular modeling perspective.
    Shi D; Zhou S; Liu X; Zhao C; Liu H; Yao X
    Biochim Biophys Acta Gen Subj; 2018 Mar; 1862(3):576-588. PubMed ID: 29203283
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structural basis for small molecule targeting of the programmed death ligand 1 (PD-L1).
    Zak KM; Grudnik P; Guzik K; Zieba BJ; Musielak B; Dömling A; Dubin G; Holak TA
    Oncotarget; 2016 May; 7(21):30323-35. PubMed ID: 27083005
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preparation of Biphenyl-Conjugated Bromotyrosine for Inhibition of PD-1/PD-L1 Immune Checkpoint Interactions.
    Kim EH; Kawamoto M; Dharmatti R; Kobatake E; Ito Y; Miyatake H
    Int J Mol Sci; 2020 May; 21(10):. PubMed ID: 32455628
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A computational study of co-inhibitory immune complex assembly at the interface between T cells and antigen presenting cells.
    Su Z; Dhusia K; Wu Y
    PLoS Comput Biol; 2021 Mar; 17(3):e1008825. PubMed ID: 33684103
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations.
    Jiang Y; Chen M; Nie H; Yuan Y
    Hum Vaccin Immunother; 2019; 15(5):1111-1122. PubMed ID: 30888929
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of PD-L1 binding sites by a combined FMO/GRID-DRY approach.
    Paciotti R; Agamennone M; Coletti C; Storchi L
    J Comput Aided Mol Des; 2020 Aug; 34(8):897-914. PubMed ID: 32185582
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of a single chain variable fragment of nivolumab that targets PD-1 and blocks PD-L1 binding.
    Shin J; Phelan PJ; Gjoerup O; Bachovchin W; Bullock PA
    Protein Expr Purif; 2021 Jan; 177():105766. PubMed ID: 32987122
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Symmetry-based ligand design and evaluation of small molecule inhibitors of programmed cell death-1/programmed death-ligand 1 interaction.
    Kawashita S; Aoyagi K; Yamanaka H; Hantani R; Naruoka S; Tanimoto A; Hori Y; Toyonaga Y; Fukushima K; Miyazaki S; Hantani Y
    Bioorg Med Chem Lett; 2019 Sep; 29(17):2464-2467. PubMed ID: 31351692
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.